Janssen Reminyl Post-Approval Plans Include Trials In Three New Indications
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Janssen’s post-approval plans for its Alzheimer’s agent Reminyl include clinical studies to support three new indications, a head-to-head trial against the market leader (Pfizer/Eisai’s Aricept), and data to support a label claim for a dual mechanism of action.